Selected article for: "clinical research and evidence totality"
Author: Venkatakrishnan, Karthik; Yalkinoglu, Oezkan; Dong, Jennifer Q.; Benincosa, Lisa J.
Title: Challenges in Drug Development Posed by the COVID‐19 Pandemic: An Opportunity for Clinical Pharmacology
  • Cord-id: fmcivv0j
  • Document date: 2020_5_28
    • ID: fmcivv0j
    Snippet: The unprecedented challenges posed by the coronavirus disease 2019 (COVID‐19) pandemic highlight the urgency for applying clinical pharmacology and model‐informed drug development in (i) dosage optimization for COVID‐19 therapies, (ii) approaching therapeutic dilemmas in clinical trial settings, and (iii) maximizing value of information from impacted non–COVID‐19 trials. More than ever, we have a responsibility for adaptive evidence synthesis with a Totality of Evidence mindset in this
    Document: The unprecedented challenges posed by the coronavirus disease 2019 (COVID‐19) pandemic highlight the urgency for applying clinical pharmacology and model‐informed drug development in (i) dosage optimization for COVID‐19 therapies, (ii) approaching therapeutic dilemmas in clinical trial settings, and (iii) maximizing value of information from impacted non–COVID‐19 trials. More than ever, we have a responsibility for adaptive evidence synthesis with a Totality of Evidence mindset in this race against time across biomedical research, clinical practice, drug development, and regulation.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory distress and adaptive evidence: 1
    • acute respiratory distress and adjunctive therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute respiratory distress and longitudinal analysis: 1, 2, 3, 4, 5
    • acute respiratory distress and lopinavir hiv ritonavir: 1
    • acute respiratory distress and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • longitudinal analysis and lupus erythematosus: 1